Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Study sponsor: AKARI Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2018-11-15Actual
Enrollment · participants1Actual
Source updated2025-05-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.